A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT ID: NCT06957080
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
1054 participants
INTERVENTIONAL
2025-04-16
2028-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045
Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy
NCT01472510
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
NCT01982435
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
NCT00284050
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
NCT00687804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose EYE103, high dose EYE103, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of ETDRS BCVA, examination by slit-lamp biomicroscopy, fundoscopy, and SD-OCT. Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EYE103 Low Dose Treatment Arm
EYE103 Low Dose Treatment Arm
EYE103
EYE103 is a humanized antibody formulated for intravitreal administration
EYE103 High Dose Treatment Arm
EYE103 High Dose Treatment Arm
EYE103
EYE103 is a humanized antibody formulated for intravitreal administration
Ranibizumab Treatment Arm
Ranibizumab Treatment Arm
Ranibizumab
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EYE103
EYE103 is a humanized antibody formulated for intravitreal administration
Ranibizumab
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be male or female ≥18 years of age.
* Have type 1 or type 2 diabetes mellitus and a HbA1c of ≤12%.
* Have a decrease in vision in the study eye determined by the investigator to be primarily the result of DME.
Exclusion Criteria
* History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
* Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
* Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
* If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
* Have had prior treatment with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
* Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept \[2 mg\], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EyeBiotech Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Miller, MD PhD
Role: STUDY_DIRECTOR
EyeBiotech Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gilbert, Arizona
Gilbert, Arizona, United States
Phoenix, Arizona
Phoenix, Arizona, United States
Scottsdale, AZ
Scottsdale, Arizona, United States
Fayetteville, AR
Fayetteville, Arkansas, United States
Bakersfield, CA
Bakersfield, California, United States
Encino, California
Encino, California, United States
Modesto, CA
Modesto, California, United States
Mountain View, CA
Mountain View, California, United States
Redlands, CA
Redlands, California, United States
Sacramento, CA
Sacramento, California, United States
Sacramento, CA
Sacramento, California, United States
Santa Ana, CA
Santa Ana, California, United States
Santa Ana
Santa Ana, California, United States
Colorado Springs, CO
Colorado Springs, Colorado, United States
Denver, CO
Denver, Colorado, United States
Durango, CO
Durango, Colorado, United States
Danbury, CT
Danbury, Connecticut, United States
Manchester, CT
Manchester, Connecticut, United States
Waterford, CT
Waterford, Connecticut, United States
Waterford,CT
Waterford, Connecticut, United States
Deerfield Beach, FL
Deerfield Beach, Florida, United States
Fort Lauderdale, FL
Fort Lauderdale, Florida, United States
Fort Myers, FL
Fort Myers, Florida, United States
Gainesville, FL
Gainesville, Florida, United States
Orlando, FL
Orlando, Florida, United States
Plantation, FL
Plantation, Florida, United States
Sarasota, FL
Sarasota, Florida, United States
Saint Petersburg, FL
St. Petersburg, Florida, United States
Tallahassee, FL
Tallahassee, Florida, United States
Tampa, FL
Tampa, Florida, United States
Tampa, FL
Tampa, Florida, United States
Winter Haven, FL
Winter Haven, Florida, United States
Joliet, Illinois
Joliet, Illinois, United States
Lemont, IL
Lemont, Illinois, United States
Oak Park, IL
Oak Park, Illinois, United States
Springfield, IL
Springfield, Illinois, United States
West Des Moines, IA
West Des Moines, Iowa, United States
Lenexa, KS
Lenexa, Kansas, United States
Wichita, Kansas
Wichita, Kansas, United States
Portland, ME
Portland, Maine, United States
Baltimore, Maryland
Baltimore, Maryland, United States
Hagerstown, MD
Hagerstown, Maryland, United States
Towson, MD
Towson, Maryland, United States
Springfield,MA
Springfield, Massachusetts, United States
Grand Rapids, MI
Grand Rapids, Michigan, United States
Edina, MN
Edina, Minnesota, United States
Minneapolis, MN
Minneapolis, Minnesota, United States
Madison, MS
Madison, Mississippi, United States
Henderson, Nevada
Henderson, Nevada, United States
Bloomfield, NJ
Bloomfield, New Jersey, United States
Cherry Hill, NJ
Cherry Hill, New Jersey, United States
Albuquerque, New Mexico
Albuquerque, New Mexico, United States
Great Neck, New York
Great Neck, New York, United States
Hauppauge, New York
Hauppauge, New York, United States
Liverpool, NY
Liverpool, New York, United States
New York, NY
New York, New York, United States
Rochester, NY
Rochester, New York, United States
Asheville, NC
Asheville, North Carolina, United States
Cary, North Carolina
Cary, North Carolina, United States
Hickory, NC
Hickory, North Carolina, United States
Wake Forest, NC
Wake Forest, North Carolina, United States
Winston Salem, NC
Winston-Salem, North Carolina, United States
Winston-Salem, NC
Winston-Salem, North Carolina, United States
Tulsa, Oklahoma
Tulsa, Oklahoma, United States
Portland, OR
Portland, Oregon, United States
Portland, Oregon
Portland, Oregon, United States
Salem, Oregon
Salem, Oregon, United States
Springfield, OR
Springfield, Oregon, United States
Bethlehem, PA
Bethlehem, Pennsylvania, United States
Erie, PA
Erie, Pennsylvania, United States
Aiken, SC
Aiken, South Carolina, United States
Beaufort, NC
Beaufort, South Carolina, United States
Beaufort, SC
Beaufort, South Carolina, United States
Bluffton, NC
Bluffton, South Carolina, United States
Charleston, SC
Charleston, South Carolina, United States
Florence, SC
Florence, South Carolina, United States
Ladson, NC
Ladson, South Carolina, United States
Ladson, SC
Ladson, South Carolina, United States
West Columbia, SC
West Columbia, South Carolina, United States
Germantown, TN
Germantown, Tennessee, United States
Hixson, TN
Hixson, Tennessee, United States
Johnson City, TN
Johnson City, Tennessee, United States
Knoxville, TN
Knoxville, Tennessee, United States
Nashville, TN
Nashville, Tennessee, United States
Abilene, TX
Abilene, Texas, United States
Amarillo, TX
Amarillo, Texas, United States
Arlington, TX
Arlington, Texas, United States
Austin, TX
Austin, Texas, United States
Bellaire, TX
Bellaire, Texas, United States
Burleson, Texas
Burleson, Texas, United States
Dallas, TX
Dallas, Texas, United States
Fort Worth, TX
Fort Worth, Texas, United States
Katy, TX
Katy, Texas, United States
Plano, TX
Plano, Texas, United States
Round Rock, TX
Round Rock, Texas, United States
San Antonio, TX
San Antonio, Texas, United States
San Marcos, Texas
San Marcos, Texas, United States
Schertz, TX
Schertz, Texas, United States
The Woodlands, TX
The Woodlands, Texas, United States
Willow Park, TX
Willow Park, Texas, United States
Salt Lake City, UT
Salt Lake City, Utah, United States
West Jordan, Utah
West Jordan, Utah, United States
Lynchburg, VA
Lynchburg, Virginia, United States
Richmond, VA
Richmond, Virginia, United States
Bellevue, Washington
Bellevue, Washington, United States
Burlington, Washington
Burlington, Washington, United States
Spokane, WA
Spokane, Washington, United States
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Buenos Aires, Argentina
Buenos Aires, , Argentina
Cordoba, Argentina
Córdoba, , Argentina
Cordoba, Argentina
Córdoba, , Argentina
Salta, Argentina
Salta, , Argentina
Salta, Argentina
Salta, , Argentina
Santa Fe, Argentina
Santa Fe, , Argentina
Aparecida De Goiania, Brazil
Aparecida de Goiânia, , Brazil
Aparecida de Goiania, Brazil
Aparecida de Goiânia, , Brazil
Assis, Brazil
Assis, , Brazil
Belo Horizonte, Brazil
Belo Horizonte, , Brazil
Blumenau, Brazil
Blumenau, , Brazil
Porto Alegre, Brazil
Porto Alegre, , Brazil
Sao Paulo, Brazil
São Paulo, , Brazil
Sao Paulo, Brazil
São Paulo, , Brazil
Sorocaba, Brazil
Sorocaba, , Brazil
Vitoria, Brazil
Vitória, , Brazil
Barranquilla, Colombia
Barranquilla, , Colombia
Bogata, Colombia
Bogotá, , Colombia
Cali, Colombia
Cali, , Colombia
Medelin, Colombia
Medellín, , Colombia
Medellin, Colombia
Medellín, , Colombia
Nagoya City, Japan
Nagoya, Aichi-ken, Japan
Hirosaki, Japan
Hirosaki, Aomori, Japan
Sakura, Japan
Sakura, Chiba, Japan
Yoshida-gun, Japan
Yoshida-gun, Fukui, Japan
Fukuoka-shi, Japan
Fukuoka, Fukuoka, Japan
Kurume City, Japan
Kurume, Fukuoka, Japan
Fukuoka-shi, Japan
Fukuoka, Higashi-ku Fukuoka, Japan
Asahikawa, Japan
Asahikawa, Hokkaido, Japan
Amagasaki, Japan
Amagasaki, Hyōgo, Japan
Mito, Japan
Mito, Ibaraki, Japan
Kita-gun, Japan
Kita-gun, Kagawa-ken, Japan
Kagoshima City, Japan
Kagoshima, Kagoshima-ken, Japan
Tokorozawa-shi, Japan
Tokorozawa-shi, Saitama, Japan
Shimotsuke-shi, Japan
Shimotsuke-shi, Tochigi, Japan
Hachioji, Japan
Hachiōji, Tokyo, Japan
Meguro-ku, Japan
Meguro-ku, Tokyo, Japan
Taito-ku, Japan
Taito-ku, Tokyo, Japan
Ube-shi, Japan
Ube-shi, Yamaguchi, Japan
Fukushima, Japan
Fukushima, , Japan
Miyazaki, Japan
Miyazaki, , Japan
Osaka, Japan
Osaka, , Japan
Osaka, Japan
Osaka, , Japan
Osaka, Japan
Osaka, , Japan
Tokushima, Japan
Tokushima, , Japan
Tokyo, Japan
Tokyo, , Japan
Yamagata, Japan
Yamagata, , Japan
Arecibo, PR
Arecibo, , Puerto Rico
San Juan, Puerto Rico
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EYE-RES-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.